Flow Mediated Dilation in Association With Hyperuricemia
1 other identifier
observational
60
1 country
1
Brief Summary
Assess cardiovascular affection and subclinical atherosclerosis in patients with systemic lupus using the non invasive flow mediated dilation. evaluate the role of uric acid as independent marker of cardiovascular risk in systemic lupus patient
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jul 2022
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 21, 2022
CompletedFirst Posted
Study publicly available on registry
April 22, 2022
CompletedStudy Start
First participant enrolled
July 30, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 27, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 27, 2023
CompletedJuly 20, 2022
July 1, 2022
5 months
March 21, 2022
July 18, 2022
Conditions
Outcome Measures
Primary Outcomes (2)
percentage of SLE patients who have premature atherosclerosis based on abnormal flow mediated dilation FMD in assiciation with hyperuricemia as predictors of cardiovascular affection in SLE patient
about 1 yrs
percentage of hyperuricemic patients wh have premature atherosclerosis based on flow mediated dilation
about 1 yrs
Study Arms (3)
normal FMD
SLE femals patientd with normal flow mediated whose ages from 18 to 45yrs
abnormal FMD
SLE femals with abnormal flow mediated dikation ages between 18 to 45yrs old
Normal female
normal femals whise ages from 18 to 45yrs old
Interventions
flow mediated dilation in brachial artery
Eligibility Criteria
femals patient whose age from 18 to 45yrs old
You may qualify if:
- female patient with SLE aged more than 18
You may not qualify if:
- male patients
- patient with established cardiovascular disease, patients with end stage renal disease
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Assuit University
Asyut, Egypt
Related Publications (2)
Hayden MR, Tyagi SC. Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle. Nutr Metab (Lond). 2004 Oct 19;1(1):10. doi: 10.1186/1743-7075-1-10.
PMID: 15507132BACKGROUNDCrawley WT, Jungels CG, Stenmark KR, Fini MA. U-shaped association of uric acid to overall-cause mortality and its impact on clinical management of hyperuricemia. Redox Biol. 2022 May;51:102271. doi: 10.1016/j.redox.2022.102271. Epub 2022 Feb 17.
PMID: 35228125BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Rafaat fathy
Rafaatfathy@yahoo.com
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- principle investigator
Study Record Dates
First Submitted
March 21, 2022
First Posted
April 22, 2022
Study Start
July 30, 2022
Primary Completion
December 27, 2022
Study Completion
December 27, 2023
Last Updated
July 20, 2022
Record last verified: 2022-07
Data Sharing
- IPD Sharing
- Will not share